The proper treatment of brain metastases continues to be a challenge for oncologists given the variability of individual patients' prognoses and the variety of treatment options available to address brain metasteses. There have been efforts since the 1990s to develop prognostic indices and nomograms to help clinicians determine the best approach for individuals with secondary malignant neoplasms of the central nervous system. A literature search was performed to identify the existing prognostic tools published between January 1995 and January 2017. While there have been several reported indices, many are limited by the number of patients analyzed or lack of generalizability. The most robust prognostic tools available are the Disease Specific Graded Prognostic Assessment and the Barnholtz-Sloan nomogram, both of which have online tools available to help clinicians. While these tools are helpful in stratifying different patients' outcomes, they are limited by their retrospective nature and likely underestimate survival in the modern era, where there is a rapidly growing arsenal of systemic agents available to patients with metastatic disease.
incidence of BMs is increasing due to improved therapeutics, resulting in longer survival from initial cancer diagnosis. Advances in imaging have enabled more accurate screening and staging, contributing to this increase. Moreover, early detection of subclinical BMs results in improved survival compared to historical series where patients would live 3 to 4 mo with surgery or radiation therapy.
2 This is partially due to lead time bias and also improved outcomes with treatment of low volume disease.
Despite what has historically been a patient cohort with a poor prognosis, there has been a great deal of heterogeneity with regard to individual patient outcomes. Beginning in the 1990s, there was a growing interest in developing prognostic indices to guide clinical treatment decision making, to provide a more accurate prognoses, and to direct clinical trial design.
Initial efforts to develop prognostic indices have certainly helped clinicians with difficult treatment decisions but there remains significant heterogeneity within survival groups. There have been continued interest and research efforts to clarify prognostic factors for survival and incorporate them into more accurate models to predict outcomes. This evolution is necessary as systemic treatment for different cancer pathologies has dramatically influenced the prognosis of many solid tumors and ultimately the impact of intracranial disease. The ability to make personalized treatment recommendations for patients with secondary malignant neoplasm of the central nervous system is of critical importance.
METHODS
An electronic search was conducted via PubMed/MEDLINE, using the Medical Subject Headings combinations of "brain metastasis" or "brain metastases" with "prognostic index" or "prognostic nomogram" for studies published between January 1995 and January 2017. A similar search was conducted via Google Scholar, Scopus, and Cochrane Library. A secondary search was conducted by reading the reference lists of the articles found in the primary electronic search process. The following types of studies were included in this review: (1) retrospectively generated indices or nomograms, (2) validation studies, and (3) retrospective studies that identified prognostic factors. All studies included in the review were published in English. The initial search process had no limitation with regard to the number of patients included in the published analysis. In the final manuscript, studies of less than 75 patients were excluded from detailed incorporation in order to limit the length of the review. The final selected nomograms were then grouped into disease site-specific categories including gastrointestinal (GI), breast, lung and melanoma, and general prognostic indices.
RESULTS
The search resulted in a total of 515 articles and 462 were excluded on the basis of the title and abstract alone. Studies were often excluded because their objective was to determine the risk of developing BMs or were investigating singular factors that could predict outcomes in patients with BMs The remaining 53 could not be unequivocally dismissed on the basis of the title and abstract, so the article was reviewed in full. Twenty additional articles were excluded at this time. Seventeen of these were excluded due to analysis of less than 75 patients. Another 3 were excluded because they were indices used to predict the risk of developing BMs rather than prognosis of BMs. An additional 10 articles were identified by analyzing the works cited from the existing articles (Figure) . This resulted in a total of 43 articles that were incorporated into this review of which 26 involved retrospectively generated indices or nomograms, 2 were independently published validation studies, and 15 were articles identifying prognostic factors.
General Prognostic Indices
One of the most well-known, general classification systems for patients with BMs was developed by the Radiation Therapy Oncology Group (RTOG) using a recursive partitioning analysis (RPA) strategy. Analysis was performed on 1200 evaluable patients prospectively enrolled on 3 RTOG trials (79-16, 85-28, and 89-05) conducted between 1979 and 1993 that were investigating whole brain radiation therapy (WBRT) regimens ± administration of misonidazole, a radiosensitizing agent. Available patient-related variables included age, Karnofsky Performance Score (KPS), neurological function, and neurological signs and symptoms (ie, headache, seizures, and visual disturbances). Tumor-related factors included primary pathology, status of primary lesion, presence of extracranial systemic metastases, number of BMs, location of BMs, and time interval between diagnosis and development of BMs. Treatment-related parameters that were available from these 3 trials included prior surgery to the brain, total radiation dose received, and response to radiation as assessed at first follow-up. RPA was used to establish prognostic groups by determining statistically significant variables using modified Wilcoxon statistics. A KPS ≥ 70 resulted in the greatest difference between groups with a median survival of 7.1 mo vs 2.3 mo. Other predictors of poor prognosis included age < 65 yr, uncontrolled primary lesion, and evidence of other systemic metastases. Using these 4 variables, 3 classes were created: class I (KPS ≥ 70, primary controlled, age < 65 yr, and BMs only), class II (not class I or III), and class III (KPS < 70) with median overall survivals (OS) of 7.1, 4.2, and 2.3 mo, respectively 3 (Table) . This classification system was validated in RTOG 91-04, a randomized study of 445 patients investigating different WBRT regimens Lorenzoni et al 6 retrospectively analyzed 110 consecutive patients treated with Gamma Knife (Elekta AB, Stockholm, Sweden) in Belgium, excluding patients with more than 10 BMs at the time of stereotactic radiosurger (SRS). The basic score for BMs (BSBM) was generated by assigning a 0 or 1 for 3 factors, including KPS (≥80 vs 50-70), control of primary tumor, and existence of extracranial disease. The median survival was not reached for patients with a BSBM of 3 (55% survival at 32 mo). The median survival was 13.1, 3.3, and 1.9 mo for BSBM scores of 2, 1, and 0, respectively. Their conclusion was that BSBM performed better than the RPA index and that patients presenting with RTOG-RPA class I or II, or BSBM of 2 or 3, are most likely to benefit from radiosurgery. 6, 7 Rades et al 8 retrospectively analyzed 1085 patients to develop a scoring system to predict survival of patients treated with WBRT for BMs. Patients received either a short course (5 × 4 Gy) or long course of WBRT (10 × 3 Gy or 20 × 2 Gy). Four significant factors were identified including age (≤60 vs > 60 yr), KPS (≥70 vs <70), presence of extracranial disease, interval between tumor diagnosis and initiation of WBRT (≤6 vs >6 mo). The score for each factor was determined by dividing the 6-mo survival rate, given as a percentage, by 10 and rounding to an integer. Actuarial 6-mo survivals for 4 distinct groups were 6% (score 9-10), 15% (score 11-13), 43% (score 14-16), and 76% (score 17-18) with no statistical difference within each group between patients receiving short or long course of WBRT (Table) . They concluded that a longer course of radiation with lower dose per fraction should be considered for patients with a score of 17 to 18 to minimize neurocognitive side effects that may be observed with longer survival. [8] [9] [10] Rades et al 11 followed their initial retrospective study by analyzing an expanded cohort of 1797 patients who received any radiation therapy as a part of their therapeutic intervention for BMs. The goal was not only to develop a prognostic index for survival but also for intracranial control (IC). 11 The patients were followed until death or at least 6 mo for IC and OS. They were randomly assigned to either the development group, used to identify prognostic factors, or the validation group. Variables impacting the OS index in the development group were KPS (<70 vs 70 vs >70), age (≤60 vs >60 yr), presence of extracranial metastases, number of BMs (1 vs 2-3 vs ≥4), and interval from tumor diagnosis to WBRT (≤6 vs >6 mo). Total scores were generated by the summation of scores assigned for each of the 5 variables to create the OS index. This analysis was then applied to the validation group, and 6-mo survival rates were found to be 7% (score 15-19), 39% (score [20] [21] [22] [23] [24] [25] , and 79% (score 26-30; Table) . IC was dependent on KPS, tumor type, number of BMs, and the interval from tumor diagnosis to WBRT. In addition to the utility of using the OS index to determine duration of a patient's WBRT course, the recommendation was to consider aggressive local therapy such as resection or SRS for patients with favorable prognostic scores and poor/intermediate IC scores. An example would be a young high-performing patient with a histology that demonstrated poor IC such as colorectal cancer. . This new prognostic index was intended to address limitations of previous prognostic nomograms. Analysis of age, sex, KPS, histologic characteristics, interval from initial diagnosis to time of presentation with BMs, number of BMs, and patients with brain and bone-only metastases were used to derive the "Graded Prognostic Assessment" (GPA). Multivariate analysis showed that only age (>60 vs 50-59 vs <50), KPS (<70 vs 70-80 vs 90-100), extracranial metastases (yes vs no), and number of metastases (1 vs 2-3 vs >3) were significant and therefore were included in the scoring system. A score was generated by allocating 0, 0.5, or 1 for each prognostic factor resulting in a total score from 0 to 4. Four prognostic groups were identified using the GPA scoring system with median survival times of 11.0 (score 3.5-4.0), 6.9 (score 3), 3.8 (score 1.5-2.5), and 2.6 mo (score 0-1). 12 This newly generated index was compared to the RTOG-RPA, Score Index for Radiosurgery (SIR), and BSBM indices. GPA was found to be as prognostic as the RPA with less subjectivity in addition to being able to define 4 distinct subgroups as opposed to 3. The GPA was also better than the SIR and BSBM showing a greater statistically significant difference between groups. 12 The GPA index was subsequently externally validated in a cohort of 140 patients with BMs treated with Gamma Knife (Elekta AB) SRS at the University of Minnesota. There was a statistically significant difference in median survival between the 4 GPA groups; however, survival times were longer in this modern cohort likely due to the ability to provide SRS and improved systemic agents for extracranial disease. Patients on the RTOG trials were enrolled and treated between 1979 and 2001, whereas the Minnesota validation cohort was treated between 2005 and 2006. 
Site-Specific Prognostic Tools
The clinical progression of metastatic disease varies considerably between different primary histologies and their individual clinical response to systemic agents. As a result, this has led several groups to analyze site-specific prognostic indices. Golden et al 14 developed the Golden Grading System (GGS) in a cohort of 479 patients treated with SRS with or without WBRT. They GGS index allocated a 0 or 1 based on the patient's age (≥65 vs <65), KPS (≥70 vs <70), and evidence of extracranial metastases. They applied the RPA, GPA, and BSBM to their data. All 4 systems provided good models for OS in the combined cohort, although there was significant variability when the scoring systems were used for different primary sites (lung, breast, and melanoma) supporting further investigation into primary diseasespecific prognostic indices. 14 The first prognostic index to address the difference between primary malignancies was the Disease Specific Graded Prognostic Assessment (DS-GPA). The DS-GPA was generated by retrospectively analyzing data from 5067 patients who received radiation therapy for BMs at 11 different institutions between July 1985 and August 2007. After excluding patients with incomplete data or who were being treated for recurrent BMs, there were a total of 4259 patients available for analysis. Similar analyses, as outlined above for the GPA, were performed for each of the following primary malignancies: nonsmall cell lung cancer (NSCLC), small-cell lung cancer (SCLC), breast, GI, melanoma, and renal cell. The originally derived GPA was confirmed for both NSCLC and SCLC. However, for melanoma and renal cell carcinoma, only KPS and number of BMs were statically significant predictors for survival, while for breast and GI primaries, only KPS was predictive.
A limitation of these prognostic systems is that they provide group rather than individualized estimations of patients' survival. Barnholtz-Sloan et al 15 addressed this issue by retrospectively analyzing the same patient cohort used to develop the GPA in addition to patients enrolled on RTOG trials 01-18 and 01-19. Several factors were analyzed examining their impact on survival using Cox proportional hazards regression, recursive partition analysis, and random survival plots. These models were felt to be superior to the RTOG-RPA and DS-GPA scoring systems. A nomogram was built that included primary site and histology, status of primary disease, extracranial disease status, age (continuous variable), KPS (≥70 vs <70), and number of brain lesions (single vs multiple; Table) . 15 
Lung
Lung cancer continues to be the one of the most common primary malignancies, with an estimated 224 390 cases and 158 080 deaths in 2016. 16 Approximately 50% to 60% of BMs originate from lung primaries leading to a significant portion of this mortality rate. 17 The existence of BMs at the time of diagnosis in patients with NSCLC is 22% and up to 40% of patients with NSCLC will eventually develop BMs. 17, 18 Patients with SCLC have a 50% risk of developing BMs within the first 2 yr of their diagnosis. 19 Rades et al 20 retrospectively analyzed 172 patients with SCLC treated with WBRT alone to evaluate prognostic factors to assist in individualizing patient treatment. Patients were assigned to either the development group (86 patients) or the validation group (86 patients). A scoring system was generated by taking the 6-mo survival rate (in %) and dividing by 10 for each of the 3 statistically significant prognostic factors including KPS (≥70 vs <70), number of BMs (1-3 vs ≥4), and presence of extracranial metastases. Three distinct prognostic groups (A-C) were then defined and 6-mo survival rates in the development group were 3% in group A, 40% in group B, 89% in group C, with near identical rates found in the validation cohort. 20 The same group performed an additional analysis of 514 patients with NSCLC treated with WBRT alone and found the prognostic factors to be gender, KPS (≥70 vs <70), and presence of extracranial metastases. Similar methods were used as were done in SCLC analysis and the 6-mo survival rates in the test cohort were 9% for group A (score 5-9), 54% for group B (score 11-12), and 78% for group C (score 15). The comparison of survival rates between the prognostic groups in the test cohort and validation cohort did not reveal any statistically significant differences. 21 Their recommended use of this data was to consider a short course WBRT (5 × 4 Gy) for group A (poor prognosis), standard course (10 × 3 Gy) for group B (intermediate prognosis), and a more protracted course (20 × 2 Gy) for group C patients (good prognosis). The lower dose per fraction was recommended to provide a more durable response and decrease the risk of long term neurocognitive deficits. 9, [20] [21] [22] The RTOG-RPA scoring system was confirmed to properly stratify NSCLC patients into 3 distinct groups with different survivals; however, there was a large variability within the class III (KPS < 70), suggesting that additional variables are needed to improve the index. 23 , 24 Nieder et al 25 evaluated 7 different prognostic indices in a group of 183 patients with NSCLC treated with WBRT with or without radiosurgery or surgical resection. The only scoring systems that generated statistically significant different prognostic groups in this patient population were the RTOG-RPA, BSBM, and GPA. 25 Their conclusion was that the 4-tiered GPA scoring system was favored for assessing prognosis prior to treatment in patients with BMs from NSCLC. 25 Cumulative intracranial tumor volume (CITV) was found to enhance the prognostic value of the lung DS-GPA model in a study by Marcus et al. 26 A retrospective analysis of 365 patients treated with SRS for BMs found that using a cut-off of 4 cm 3 for CITV provided the greatest survival discrimination at 1 yr. When added to the original variables included in the lung DS-GPA, there was a significant improvement in the prognostic value of the model based on statistically significant net reclassification improvement >0 of 0.430 and net reclassification improvement of 0.029, which both assess the discriminatory ability of a model. This was redemonstrated in an independent cohort of 1638 lung cancer patients with BMs treated with SRS. 26 Therapies targeting epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) gene rearrangements have recently demonstrated that there is significant variability in survival of patients with lung adenocarcinoma. 27, 28 Retrospective analysis of 1521 patients with adenocarcinoma of the lung was performed to assess for the prognostic significance of EGFR, ALK, and KRAS mutation status on median survival. This study concluded that EGFR and ALK gene alterations were associated with both delayed onset on BMs and prolonged median survival. 29 Sperduto et al 30 used these findings to create a new Lung-molGPA by analyzing 2186 NSCLC patients (1521 adenocarcinomas and 665 nonadenocarcinomas) with newly diagnosed BMs treated between 2006 and 2014. Variables that were investigated included the 4 original prognostic factors from the lung DS-GPA (age, KPS, extracranial metastases, and the number of BMs) as well as gene mutation status (EGFR, ALK, or KRAS positivity), pack-years of tobacco use, sex, race, histopathologic grade, and total volume of BMs. Multiple Cox regression analysis identified the original lung DS-GPA factors to be significant as well as EGFR and ALK alteration in patients with adenocarcinoma (Table) . The median survival of all patients was 12 mo compared to 7 mo for NSCLC patients in the original DS-GPA analysis. Additionally, high-performing lung adenocarcinoma patients with no evidence of extracranial disease that has evidence of an EGFR or ALK gene alteration leading to a favorable LungmolGPA scores of 3.5 to 4.0 had a median survival of nearly 4 yr, supporting an aggressive treatment approach (Table) . 30 
Gastrointestinal
GI malignancies remain the second most common malignancy in both men and women and are the second leading cause of cancer related death in the United States with an estimated 304 930 new cases and 153 030 deaths in 2016. 16 The 2 GI primary malignancies that have the greatest mortality are colorectal and pancreas, both leading to an estimated 49 190 and 41 780 deaths in 2016, respectively. 16 It has been reported that 4% to 6% of BMs arise from a GI primary malignancy. 17 The improved control of local disease and extracranial metastases has led to a rise in the incidence of BMs from GI malignancies as patients are living long enough to develop BMs, as well as longer interval between initial diagnosis and development of intracranial disease. 31 The generation of the RTOG-RPA and GPA classification systems included a variety of different primary pathologies but these nomograms were generated with a preponderance of breast and lung cancer patients. 3, 12 The DS-GPA classification system only found KPS to be a statistically significant prognostic factor for patients with GI primaries. This was subsequently validated in a separate cohort of 209 patients. 32, 33 Pietrantonio et al 34 conducted a multicenter study of 227 patients with colorectal cancer diagnosed with BMs in an effort to generate a diagnosis-specific nomogram to predict survival. Multivariate analysis found that favorable prognosis was associated with age (continuous variable), KPS (<70 vs 70-80 vs 90-100), supratentorial site of BMs, and number of BMs (1 vs 2-3 vs >3). The new nomogram was subsequently validated in an external data set of 119 patients. 34 Despite evidence that patients with KRAS mutations have a higher incidence of BMs, it was found that KRAS mutation status was not a statistically significant prognostic factor. 35, 36 This was consistent with another small retrospective analysis that showed KRAS status was not a prognostic factor. 37 Hepatocellular carcinoma (HCC) continues to be one of the most common cancers in the world with approximately 700 000 deaths each year. 38 Park et al 39 retrospectively reviewed 97 patients with BMs from HCC in an effort to develop a nomogram specifically for this patient population. Their internally validated nomogram includes ECOG PS, Child-Pugh classification, alpha-fetal protein (AFP) level, and treatment aim (definitive, adjuvant, or salvage WBRT). The median OS for the entire study population was 3.5 mo. A nomogram was generated with a concordance index of 0.74. 39 Lim et al 40 developed an HCC diagnosis-specific GPA index by analyzing 118 patients with BMs from HCC. The model constructed included number of BMs, AFP level, and Child-Pugh classification. Treatment modality was not included in the HCC GPA index to prevent selection bias and to provide a prognostic tool prior to the initiation of therapy. 40 Kim et al 41 also developed a prognostic index by retrospectively evaluating 95 patients with HCC and found on multivariate analysis that ECOG PS, Child-Pugh class, AFP level, number of brain lesions, and treatment modality were associated with survival. A prognostic index was created using the 4 pretreatment variables and 3 groups were created based on the number of risk factors 0-1, 2, or 3-4 with median survival times of 5.8, 2.5, and 0.6 mo, respectively. 41 
Breast
Breast cancer continues to be the most prevalent primary malignancy among woman in the United States with an estimated 246 660 new cases and 40 450 deaths in 2016. 16 In contrast to other primary pathologies, nearly a half of breast cancer patients who develop BMs will die from neurological death. 42 Only 12% of patients included in the original RTOG-RPA had a breast primary. Several efforts have been made to identify other prognostic factors to create a more accurate breast cancer-specific prognostic classification system. 33, [43] [44] [45] [46] [47] Le Scodan et al 47 looked to validate the RTOG-RPA classification system and determine if there were independent prognostic factors for patients with BMs from breast cancer. One hundred thirty-two patients receiving radiation therapy for BMs were retrospectively analyzed, and on multivariate analysis RTOG-RPA class III lymphopenia (defined as ≤0.7 G/L) and hormone negative status were independent prognostic factors for poor survival. 47 Claude et al 43 retrospectively reviewed 120 patients with BMs from breast cancer receiving radiation therapy and performed a multivariate regression analysis looking at age, PS, tumor characteristics, and pretreatment modalities. Analysis showed only KPS and lymphopenia (defined as ≤0.7 G/L) to be statistically significant factors on multivariate analysis. 43 Park et al 44 retrospectively analyzed 125 women with breast cancerrelated BMs receiving radiation therapy and assessed the following data: age, PS, hormone receptor status, human epidermal growth factor receptor 2 (HER2) expression, RTOG-RPA class, interval between diagnosis of primary tumor and detection of BM, and treatment modality. On multivariate analysis, only poor PS (ECOG ≥ 2), HER2 positivity, and no additional systemic treatment were identified as risk factors for worse prognosis. 44 Niwińska et al 46 prospectively collected data on 441 consecutive patients with BMs from breast cancer mainly treated with WBRT. Three classes were created with class I including patients with 1 or 2 BMs, without extracranial disease or with controlled extracranial disease, and with KPS of 100. Class III included patients with multiple BMs with KPS of ≤60, and class II included all other cases. The median survival of patients within classes I, II, and III was 29, 9, and 2.4 mo, respectively. 46 A comparison of published scores was performed by Nieder et al, 45 who evaluated 5 previously published prognostic scoring systems including RTOG-RPA, SIR, BSBM, GPA score, and the second prognostic index developed by Rades et al 11 in a group of 83 patients. There were limited data regarding hormone and HER2 receptor status in their patient cohort. The systems that performed the best were the RTOG-RPA and SIR; however, several disagreements between parameters that effect outcomes were noted. A new 4-tiered scoring system was developed that included KPS, extracranial metastases, interval from first cancer diagnosis, and number of BMs. 45 The DS-GPA classification developed by Sperduto et al 12 included 642 breast cancer patients with BMs and initially only found KPS to be a prognostic factor on multivariate analysis. 32 This model was further adjusted by looking at human epidermal growth factor receptor 2 (HER2) and estrogen receptor and progesterone receptor (ER/PR) status using both multivariate Cox regression and RPA analyses. The new breast cancer DS-GPA index found KPS (≤50, 60 vs 70-80 vs 90-100), genetic subtype (basal vs luminal A vs HER2 vs luminal B, in order of increasing HR), and age (≥60 vs <60) to be important prognostic factors. 48 These factors were included in an updated summary of the DS-GPA (Table) . 33 The fact that extracranial metastasis was not identified as a prognostic factor in the DS-GPA as compared to the RTOG-RPA is likely due to advancements in systemic therapy since the period that the RTOG-RPA was developed. Furthermore, using the DS-GPA removes the subjectivity of determining if extracranial disease is controlled. 46 This is supported by the findings of Niwińska et al 46 who defined class I patients as those with 1 to 2 BMs, KPS of 100, and without extracranial disease or controlled extracranial disease; however, using the DS-GPA may help to remove some of the subjectivity of determining if extracranial disease is controlled. 46 Additionally, while HER2 status is by itself a poor prognostic factor, in the post-trastuzimab era the survival of HER2-positive breast cancer patients is the longest of all biologic subtypes. 49 
Melanoma
There are an estimated 76 380 cases of cutaneous melanoma in the United States. While the highest number of BMs comes from lung, it has been shown that melanoma has the highest propensity to metastasize to the brain. 16, 50 The rate of BMs in patients with melanoma is likely to rise with recent advances in targeted agents to control extracranial disease. 51 , 52 Morris et al 53 retrospectively analyzed 112 patients who received WBRT at a single institution for BMs from cutaneous melanoma in order to assess for factors predictive for survival. Univariate and multivariate analysis identified RTOG-RPA class, progression of disease in the brain on imaging prior to WBRT, presence of leptomeningeal disease, and number of extracranial metastatic sites to be statistically significant factors. A score was generated from each patient using the following formula: number of extracranial metastatic sites + (RTOG-RPA class × 2) + (2 if progression of disease in the brain was noted on imaging) + (4 if evidence of leptomeningeal disease). Five distinct survival groups were generated with median survival times of 138, 80, 42, 18, and 15 d. 53 While a large portion of patients included in the melanoma DS-GPA received SRS as a part of their treatment, the majority of patients did not receive SRS alone. Chowdhury et al 54 retrospectively reviewed 86 consecutive patients with BMs from melanoma treated with SRS alone at a single institution between 2009 and 2014. Cox proportional hazard modeling identified clinical risk factors for OS as well as distant brain failure. Scores were created based on weighted regression coefficients. After analyzing factors that included gender, age, KPS, presence of extracranial disease status, number of BMs, BRAF gene mutation status, metastases volume, treatment volume, and use of peri-or post-SRS systemic treatment, a risk score for OS was developed that included KPS (>80 vs ≤80), extracranial disease status (absent vs active/stable), number of lesions (1 vs 2-4 vs >4), and gender. Median OS for the low-risk group (score 0-3) was not reached after 37.4 mo of follow-up, while the median OS for the moderate-risk (4-6) and the high-risk groups (6.5-10) was 7.6 and 2.4 mo, respectively. A prognostic score for IC failure was found to only include KPS, extracranial disease status, and number of BMs (1 vs 2-3 vs >3) leading to 3 risk groups. The new survival score had a higher Harrell's C index or 0.72 than either of the RTOG-RPA or melanoma DS-GPA with c-indices of 0.57 and 0.66, respectively. The authors commented that this tool could be valuable in identifying patients with high prognostic scores for IC failure suggesting subclinical micrometastatic disease in their brain that may benefit from WBRT instead of SRS based on their risk of distant brain failure. 54 Significant recent advancements in systemic therapeutic options for patients with metastatic melanoma have led to improved OS. Therefore, OS rates reported in the RTOG-RPA and DS-GPA may not be applicable in a more modern cohort of patients with improved and effective systemic treatment options now available. Gorovets et al 55 recently examined 87 patients treated with SRS alone for metastatic melanoma and found that median OS was 10.1 mo vs RTOG-RPA prediction of 4.2 mo and DS-GPA prediction of 4.7 mo. It was noted that among all patients as well as patients receiving immunotherapy and/or BRAF inhibition, the RTOG-RPA and DS-GPA scoring systems still remained prognostic indicators but with longer survival for each scoring group when compared to what was originally reported.
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CONCLUSION
With improved extracranial control, the incidence of BMs will likely rise and more patients may eventually succumb to neurological death. With the extensive array of prognostic indices that are available for patients with BMs, selecting an optimal treatment strategy individualized to the patient's prognosis is often difficult. We have attempted to summarize the wide array of available nomograms and have attempted to highlight the largest and perhaps most useful publications (Table) . A remarkably consistent finding throughout most published series is the influence of PS on OS. 3, [5] [6] [7] [8] 11, 12, 14, 15, 20, 20, [30] [31] [32] [33] [34] 39, 41, [43] [44] [45] [46] [54] [55] [56] [57] [58] While these prognostics indices are highly useful, they also may contain some limitations. Almost all of the prognostic indices or nomograms for patients with BMs were developed by retrospective analyses which possess inherent limitations. It is also difficult to generalize existing prognostic tools to malignant histologies that have a low incidence of intracranial spread. The continued improvement of local treatments for BMs and or new systemic treatments for different pathological diagnoses will always lead to underestimation and inaccuracy in predicting survival outcomes. However, identifying patients who have a very poor prognosis is important as data support the use of best conservative management or shortened courses of treatment in certain primary histologies. [59] [60] [61] Conversely, it is equally essential to identify patients with excellent prognoses based on these available tools who may benefit NEUROSURGERY VOLUME 82 | NUMBER 5 | MAY 2018 | 601 the most from aggressive local therapies such as WBRT with SRS boosting, more protracted courses of WBRT, hippocampal avoidance WBRT, and or the use of memantine to limit neurocognitive dysfunction. 8, 9, 56, 62 The use of accurate prognostic tools is necessary for clinical trial stratification to help determine which patients could truly benefit from experimental therapies. In an era where systemic agents to address metastatic cancer are developing rapidly, it will be important to continuously update existing prognostic tools and assess for new prognostic factors in patients with BMs
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